Navigation Links
UAB study shows investigational drug may treat biliary cancers
Date:4/15/2008

BIRMINGHAM, Ala. -- Laboratory studies by University of Alabama at Birmingham (UAB) researchers have shown that the investigational drug triphendiol (NV-196) causes cell death in pancreatic and bile duct cancer cell lines, slows tumor growth and sensitizes tumors to chemotherapy treatments.

The findings were presented April 13 by Ewan Tytler, Ph.D., assistant professor in the UAB Department of Surgery, Gastrointestinal Section, at the annual meeting of the American Association for Cancer Research (AACR).

Tytler and his colleagues assessed the potential of triphendiol as a treatment for pancreatic adenocarcinoma using three representative cell lines. Triphendiol induced cell death in all three cell lines and pre-treating the cell lines with triphendiol increased the effectiveness of chemotherapy. Animal model studies showed that triphendiol in combination with chemotherapy inhibited tumor growth more effectively than each drug alone.

In our laboratory studies, triphendiol is more potent at inducing cell death in pancreatic and bile duct cancer cells compared to the chemotherapy drug gemcitabine alone at up to 10-fold lower concentrations, Tytler said. Of course, there is still much work to be done before this could become a treatment protocol for cancer patients but our findings are promising and validate the continued development of triphendiol as a possible pancreatic cancer therapy.

Triphendiol is being developed by Marshall Edwards Inc., as a treatment for late stage pancreatic and gall bladder cancer and recently received orphan drug status by the U.S. Food and Drug Administration. Triphendiol has been licensed by Novogen to Marshall Edwards Inc., who funded Tytlers study.

Tytler said that there is an urgent need for new pancreatic cancer treatments because fewer than 20 percent of patients are candidates for surgery. Current treatment is limited to chemotherapy, which is not always effective, as most tumors are resistant to or become resistant to the commonly used chemotherapy drug for pancreatic tumors, gemcitabine.


'/>"/>

Contact: Jennifer Lollar
jpark@uab.edu
205-934-3888
University of Alabama at Birmingham
Source:Eurekalert

Related medicine news :

1. Study shows that high-dose, high-frequency interferon produces no additional benefit
2. Study finds media coverage of breast cancer focuses too little on prevention
3. USC study finds evidence of gender-related differences in development of colon cancer
4. New study in JCSM finds that obesity can predict upper airway obstruction amongst children
5. Study shows increase of hip and knee replacements in the US
6. Study shows decline in work disability due to rheumatoid arthritis
7. Study details cost-effectiveness of rheumatoid arthritis treatments for Medicare recipients
8. Study sheds light on deadly lung disease
9. NovoCure presents results from breast cancer pilot study
10. Mayo-led study finds smoking related to subset of colorectal cancers
11. National hospice study reveals gaps in service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... Dr. James Maisel will present ... Island Chapter on June 4, 2016, 1:30-3:30 pm at the Farmingdale Public Library. ... Retina Group of New York , is a Board Certified ophthalmologist who completed ...
(Date:5/26/2016)... ... 26, 2016 , ... Leadership of Life Science Logistics (LSL), ... has earned its ISO 13485 certification, indicating the company’s quality control system for ... policies associated with ISO quality standard 13485. , BSI Group America, Inc., ...
(Date:5/26/2016)... CA (PRWEB) , ... May 26, 2016 , ... ... be offering campers a multitude of activities from daily practices, arts & crafts, ... , Camp Directors Amber East-D’Anna and Christy Evans have combined backgrounds in kids’ ...
(Date:5/26/2016)... ... May 26, 2016 , ... Power Systems, ... the first PowerWave Instructor Certification Course in Stoughton, Massachusetts. The course was led ... professional through the 8 hour interactive course to qualify participants as certified PowerWave ...
(Date:5/26/2016)... ... May 26, 2016 , ... A health conscious snack that doesn't sacrifice taste? ... has ignited an undeniable buzz in the protein product community by offering an alternative ... These doughnuts are packed with 11 grams of protein and made from a healthy ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , May 25, 2016  Granger Diagnostics today ... test for wounds and infections. This test ensures ... and select viruses. The test requires only a ... David G. Bostwick , MD, ... to facilitate wound healing: "We are excited to ...
(Date:5/24/2016)... Niederländische Chirurgen haben eine ... Ärzten erlaubt, ihre Expertise weltweit zu teilen und ... Streaming mit einer Instant-Messaging-Funktion und der Möglichkeit, in ... Europa, Afrika, Asien und den USA ... registriert. Information und Weiterbildung   ...
(Date:5/24/2016)... ARANZ Medical  Ltd a specialist ... has been named the Coretex Hi-Tech Emerging Company of the ... Dr Bruce Davey , CEO of ARANZ Medical says, ... good to be recognised for the work we are doing ... in 35 countries around the world from Sub-Saharan Africa through ...
Breaking Medicine Technology: